Calidi Biotherapeutics (CLDI)Director bought ~$150K

~$150K

Approx. value · 75K sh @ $2.00

76K

Holds after · shares reported

Traded

Aug 21, 2025

Filed

Aug 26, 2025

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

1. Aug 8, 2025Company filing · Form 8-K · Material agreement, Executive changeChanged a top executive or board member, and signed an important agreement“On September 16, 2025, the Board of Directors of Calidi Biotherapeutics, Inc. (the “Company”), approved the elimination of the position of Chief Legal Officer and, as a result, the termination of the employment agreement with Ms. Wendy Pizarro Campbell (the “Employment Agreement”), effective as of October 17, 2025 (“Effective Date”).”
2. Aug 21, 2025 · this disclosureInsiderDirector purchased ~$150K of CLDI shares in the open market

What came next

1. Aug 21, 2025Insider · 3 peopleInsiders: 3 purchases (~$305K)
2. Oct 27, 2025Company filing · Form 8-K · Material agreement, Agreement endedCompleted buying or selling a business or assets, and signed an important agreement (and 1 more item)“The information in Item 1.01 above is incorporated herein by reference.”
3. Nov 13, 2025Company filing · Form 8-K · Results, Reg FDReported its results, and shared information with investors
4. Dec 12, 2025InsiderDirector sold ~$1.2K of CLDI shares in the open market

How to read SEC Form 4

Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.

Full guide: What is an SEC Form 4?

What else is on file for Calidi Biotherapeutics

OQRO holds no insider, Congress, fund or contract record for Calidi Biotherapeutics dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its CLDI page.

Other recent filings by James A Schoeneck, Director

• SEC Form 4 at Kyntra Bio (KYNB)Jul 2, 2025
• SEC Form 4 at Kyntra Bio (KYNB)Mar 24, 2025
• SEC Form 4 at Kyntra Bio (KYNB)Mar 24, 2025

The full history of James A Schoeneck, Director is on the profile page.

How this filing works

• SEC Form 4
• Open-market purchase
• Rule 10b5-1 trading plans

Other disclosures at Calidi Biotherapeutics

• SEC Form 4Dec 17, 2025
• SEC Form 4Aug 26, 2025
• SEC Form 4Aug 26, 2025
• SEC Form 4Aug 26, 2025
• SEC Form 4Dec 19, 2024

Everything OQRO holds on this company is on its CLDI page.